Mineralys Therapeutics (MLYS) Earnings Analysis
Mineralys Therapeutics (MLYS) next reports earnings on 2026-08-11, consensus EPS -0.57 USD. Last quarter (2026-03-12) it beat with EPS -0.4 USD vs -0.51625 USD est (+22.5%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -13.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MLYS next report earnings?
| Next earnings date | 2026-08-11 |
|---|---|
| Consensus EPS estimate | -0.57 USD |
| Revenue estimate | n/a |
MLYS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-12 | -0.4 USD | -0.51625 USD | +22.5% | Beat |
| 2025-11-10 | -0.52 USD | -0.66 USD | +21.2% | Beat |
| 2025-08-12 | -0.66 USD | -0.78 USD | +15.4% | Beat |
| 2025-05-12 | -0.79 USD | -1.02 USD | +22.5% | Beat |
| 2024-11-11 | -1.13 USD | -0.83 USD | -36.1% | Miss |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
MLYS valuation and analyst view
| Trailing P/E | -13.18 |
|---|---|
| Trailing EPS | -1.83231 USD |
| Price / book | 3.51 |
| Dividend yield | 0.00% |
| Market cap | 1.79B |
| Analyst consensus | Buy (7 buy / 1 hold / 0 sell) |
| Avg price target | 47.5 USD |
Related research pages
Frequently asked questions
When is Mineralys Therapeutics (MLYS)'s next earnings date?
Mineralys Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.57 USD.
Did MLYS beat earnings last quarter?
In its 2026-03-12 report, MLYS posted EPS of -0.4 USD versus a -0.51625 USD estimate — a beat of 22.5%.
What is MLYS's earnings track record?
Over the last 5 reported quarters with consensus data, MLYS beat estimates 4 times (80%).
What is MLYS's current P/E ratio and EPS?
MLYS trades at a trailing P/E of -13.18 on trailing EPS of -1.8323106707677472 USD.
What do analysts rate MLYS?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 47.5 USD.